New High Fidelity CRISPR Cas9 Protein Reduces Off-target Effects for More Precise Genome Editing
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
CARLSBAD, Calif., Nov. 30, 2021 /PRNewswire/ -- For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen TrueCut HiFi Cas9 Protein* significantly minimizes off-target events while retaining maximum on-target editing efficiency. Thermo Fisher Scientific introduced the new protein to complement its growing portfolio of CRISPR genome editing solutions.
CRISPR genome editing is inherently messy, often resulting in edits in unintended locations. Limiting off-target effects is critical for applications such as translational research, drug screening and drug modeling as researchers look down the road to future therapeutic development. The Invitrogen TrueCut HiFi Cas9 Protein demonstrates near complete elimination of off-target effects compared to wild-type Cas9 in several cell types, including T cells and induced pluripotent stem cells (iPSCs), and demonstrates improved off-target profiles relative to other products on the market.
"Our pharma and biotech customers are looking for highly precise, accurate solutions to harness the power of CRISPR genome editing," said Brandon Pence, vice president and general manager of cell biology at Thermo Fisher Scientific. "Nothing is more disappointing than to find out months after an edit that the biological response you are measuring was due to an unintended off-target edit. The new Invitrogen TrueCut HiFi Cas9 Protein offers researchers the confidence that their edits took place where they intended, not somewhere else in the genome."
Thermo Fisher's growing portfolio of genome editing tools also includes the recently redesigned Invitrogen TrueDesign Genome Editor, a free online tool to help scientists easily design their genome editing experiments. The software's predictive algorithm scores each guide RNA, giving scientists the insights they need to select the right materials to limit off-target effects and perform a successful edit. The Invitrogen TrueDesign Genome Editor supports experiment types including gene knockouts, fluorescent tagging, insertions, deletions, SNP edits and replacements.
To learn more about the Invitrogen TrueCut HiFi Cas9 Protein, visit thermofisher.com/cas9.
For more information on Thermo Fisher's full CRISPR genome editing portfolio, visit thermofisher.com/crispr.
*For research use only. Not for use in diagnostic procedures.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $35 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 90,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.
Media Contact Information:
Mauricio Minotta
Phone: 760-805-5266
Email: mauricio.minotta@thermofisher.com
Jen Heady
Phone: 413-237-5141
Email: jheady@greenough.biz
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-high-fidelity-crispr-cas9-protein-reduces-off-target-effects-for-more-precise-genome-editing-301433885.html
SOURCE Thermo Fisher Scientific